Human antibodies specific for TGFβ2

Details Human antibodies specific for TGFβ2 Human antibodies specific for TGFβ2

2003-07-23

2008-05-06

Gambel, Phillip (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C424S130100, C424S133100, C424S141100, C424S142100, C424S158100, C530S387100, C530S387300, C530S388100, C530S388150, C530S388230

Reexamination Certificate

active

07368111

ABSTRACT:
Specific binding members comprising human antibody antigen binding domains specific for human transforming growth factor beta (TGFβ) bind specifically isoforms TGFβ2 and TGFβ1 or both, preferentially compared with TGFβ3. Specific binding members may be isolated and utilized in the treatment of disease, particularly fibrotic disease and also immune/inflammatory diseases. Therapeutic utility is demonstrated using in vitro and in vivo models. Full sequence and binding information is provided, including epitope sequence information for particularly advantageous specific binding member which binds the active form of TGFβ2, neutralizing its activity, but does not bind the latent member.

REFERENCES:
patent: 4816397 (1989-03-01), Boss et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5091513 (1992-02-01), Huston et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5262319 (1993-11-01), Iwata et al.
patent: 5395750 (1995-03-01), Dillon et al.
patent: 5571714 (1996-11-01), Dasch et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5616561 (1997-04-01), Barcellos-Hoff
patent: 5662904 (1997-09-01), Ferguson et al.
patent: 5772998 (1998-06-01), Dasch et al.
patent: 5783185 (1998-07-01), Dasch et al.
patent: 5885793 (1999-03-01), Griffiths et al.
patent: 5962255 (1999-10-01), Griffiths et al.
patent: 6090383 (2000-07-01), Dasch et al.
patent: 6248516 (2001-06-01), Winter et al.
patent: 6331415 (2001-12-01), Cabilly et al.
patent: 6419928 (2002-07-01), Dasch et al.
patent: 6492497 (2002-12-01), Thompson et al.
patent: B-27617/88 (1989-07-01), None
patent: A 0120694 (1984-10-01), None
patent: A 0125023 (1984-11-01), None
patent: A 184187 (1986-06-01), None
patent: A 0239400 (1987-09-01), None
patent: B 0239400 (1987-09-01), None
patent: 0 324 162 (1988-12-01), None
patent: 0 368 684 (1994-03-01), None
patent: 2188638 (1987-10-01), None
patent: 2 288 118 (1995-10-01), None
patent: 9520486.3 (1995-10-01), None
patent: 9601081.4 (1996-01-01), None
patent: WO 88/06630 (1988-09-01), None
patent: WO 88/09344 (1988-12-01), None
patent: WO 90/02809 (1990-03-01), None
patent: WO 90/05144 (1990-05-01), None
patent: WO 90/14424 (1990-11-01), None
patent: WO 90/14430 (1990-11-01), None
patent: WO 90/14443 (1990-11-01), None
patent: WO 91/04748 (1991-04-01), None
patent: WO 91/10737 (1991-07-01), None
patent: WO 91/17271 (1991-11-01), None
patent: WO 92/01047 (1992-01-01), None
patent: WO 92/06204 (1992-04-01), None
patent: WO 92/09690 (1992-06-01), None
patent: WO 92/17206 (1992-10-01), None
patent: WO 92/18619 (1992-10-01), None
patent: WO 92/20791 (1992-11-01), None
patent: WO 93/06213 (1993-04-01), None
patent: WO 93/11161 (1993-06-01), None
patent: WO 93/11236 (1993-06-01), None
patent: WO 93/14782 (1993-08-01), None
patent: WO 93/17708 (1993-09-01), None
patent: WO 93/19783 (1993-10-01), None
patent: WO 93/21945 (1993-11-01), None
patent: WO 94/13804 (1994-06-01), None
patent: WO 94/18227 (1994-08-01), None
patent: WO 95/13827 (1995-05-01), None
patent: WO 97/13844 (1997-04-01), None
Lucas et al., J. Immunol. 145: 1415-1422, 1990.
Rudikoff et al., Proc Natl Acad Sci USA 79: 1979-1983, 1982.
Colman, Research in Immunology 145: 33-36, 1994.
Bouanani, M. et al., “Autoimmunity to Human Thyroblobulin,” Arthritis and Rheumatism, 34(12):1585-1593 (1991).
James, K. and Bell, G.T., “Human Monoclonal Antibody Production: Current Status and Future Prospects,” Journal of Immunological Methods, 100:5-40 (1987).
Kim, J.G. and Abeyounis, C.J., “Isolation and Characterization of Rat Carcinoembryonic Antigen,” Int. Arch. Allergy Appl. Immunol., 92:43-49 (1990).
Kim, J.G. and Abeyounis, C.J., “Monoclonal Rat Antibodies to Rat Carcinoembryonic Antigen,” Immunological Investigations, 17(1):41-48 (1988).
Portolano, S. et al., “A Human FAB Fragment Specific for Thyroid Peroxidase Generated by Cloning Thyroid Lymphocyte-Derived Immunoglobulin Genes in a Bacteriophage Lambda Library,” Biochemical and Biophysical Research Communications, 179(1):372-377 (1991).
Avrameas, “Natural Autoantibodies: From ‘Horror Autotoxicus’to ‘Gnothi Seauton’”, Immunology Today 12:154-159 (1991).
Bass et al., “Hormone Phage: An Enrichment Method for Variant Proteins With Altered Binding Properties,” Proteins, Structure, Function and Genetics 8:309-314 (1990).
Bendtzen et al., “Autoantibodies to Cytokines—Friends or Foes?,” Immunology Today 11(5):167-169 (1990).
de la Cruz et al., “Immunogenicity and Epitope Mapping of Foreign Sequences via Genetically Engineered Filamentous Phage,” J. Biol. Chem. 263(9):4318-4322 (1988).
Ditzel et al., “The Nature of the Autoimmune Antibody Repertoire in Human Immunodeficiency Virus Type 1 Infection,” Proc. Natl. Acad. Sci. USA 91:3710-3714 (1994).
Hassan et al., “Prevalence of Anti-Fab Antibodies in Patients with Autoimmune and Infectious Diseases,” Clin. exp. Immunol. 89:423-426 (1992).
Huse et al., “Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda,” Science 246:1275-1281 (1989).
Jerome et al., “Adenocarcinoma Reactive Cytotoxic T Lymphocytes Recognize an Epitope Present on the Protein Core of Epithelial Mucin Molecules,” Cellular Immunity and the Immunotherapy of Cancer, pp. 321-328 (1990).
Kang et al., “Linkage of Recognition and Replication Functions by Assembling Combinatorial Antibody Fab Libraries Along Phage Surface,” Proc. Natl. Acad. Sci. USA 88:4363-4366 (1991).
Leusch et al., “Failure to Demonstrate TNF α-Specific Autoantibodies in Human Sera by ELISA and Western Blot,” Journal of Immunological Methods 139:145-147 (1991).
Marks et al., “By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling,” Bio/Technology 10:779-783 (1992).
McCafferty et al., “Phage Antibodies: Filamentous Phage Displaying Antibody Variable Domains,” Nature 348:552-554 (1990).
Milstein, F.R.S., “Antibodies: a Paradigm for the Biology of Molecular Recognition,” Proc. R. Soc. London B 239:1-16 (1990).
Moynier et al., “The B Cell Repertoire in Rheumatoid Arthritis. I. Frequency of EBV-Inducible Circulating Precursors Producing Autoantibodies,” Journal of Autoimmunity 4:631-649 (1991).
Nossal, “Immunologic Tolerance: Collaboration Between Antigen and Lymphokines,” Science 245:147-153 (1989).
Parmley and Smith, “Antibody-Selectably Filamentous fd Phage Vectors: Affinity Purification of Target Genes,” Gene 73:305-318 (1988).
Sanz et al., “Nucleotide Sequences of Eight Human Natural Autoantibody VHRegions Reveals Apparent Restricted Use of VHFamilies,” The Journal of Immunology 142(11):4051-4061 (1989).
Sekigawa et al., “Characterization of Autoantibodies to the CD4 Molecule in Human Immunodeficiency Virus Infection,” Clinical Immunology and Immunopathology 58:145-153 (1991).
Short et al., “λ ZAP: a Bacteriophage λ Expression Vector with In Vivo Excision Properties,” Nucleic Acids Research 16(15):7583-7600 (1988).
Smith, “Filamentous Fusion Phage: Novel Expression Vectors That Display Cloned Antigens on the Virion Surface,” Science 228:1315-1317 (1985).
Tsunetsugu-Yokota et al., “Expression of an Immunogenic Region of HIV by a Filamentous Bacteriophage Vector,” Gene 99:261-265 (1991).
Winter and Milstein, “Man-Made Antibodies,” Nature 349:293-299 (1991).
Yativ et al., “The Detection of Antithyroglobulin Activity in Human Serum Monoclonal Immunoglobulins (Monoclonal Gammopathies),” Immunol. Res. 12:330-337 (1993).
International Search Report: PCT/GB92/02240.
Border et al., “Suppression of Experimental Glomerulonephritis by Antiserum Against Transforming Growth Factor β1,” Nature, 346:371-374 (1990).
Dasch et al., “Monoclonal Antibodies Recognizing Trans

Affiliated with

Also associated with

Rating

Human antibodies specific for TGFβ2 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Human antibodies specific for TGFβ2, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human antibodies specific for TGFβ2 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3984964